The measles virus (MeV), a member of the paramyxovirus family, is an important cause of pediatric morbidity and mortality worldwide. In an effort to provide therapeutic treatments for improved measles management, we previously identified a small, non-nucleoside organic inhibitor of the viral RNA-dependent RNA polymerase by means of high-throughput screening. Subsequent structure−activity relationship (SAR) studies around the corresponding pyrazole carboxamide scaffold led to the discovery of 2 (AS-136a), a first generation lead with low nanomolar potency against life MeV and attractive physical properties suitable for development. However, its poor water solubility and low oral bioavailability (F) in rat suggested that the lead could benefit from further SAR studies to improve the biophysical characteristics of the compound. Optimization of in vitro potency and aqueous solubility led to the discovery of 2o (ERDRP-00519), a potent inhibitor of MeV (EC 50 = 60 nM) with an aqueous solubility of approximately 60 μg/mL. The agent shows a 10-fold exposure (AUC/C max ) increase in the rat model relative to 2, displays near dose proportionality in the range of 10−50 mg/kg, and exhibits good oral bioavailability (F = 39%). The significant solubility increase appears linked to the improved oral bioavailability.
■ INTRODUCTION
The paramyxoviruses family is comprised of nonsegmented, negative strand ribonucleic acid (RNA) viruses that are primarily responsible for acute respiratory diseases. The family includes major human and animal pathogens such as measles virus (MeV), human parainfluenza virus (HPIV), mumps virus, respiratory syncytial virus (RSV), and the Newcastle disease virus. Despite the existence of an effective vaccine protecting against MeV infection, we have witnessed in the recent past an increasing number of cases particularly in the developed world. 1, 2 For example, in the United States from January 1 through May 21 of 2011, 118 cases were reported across 23 states according to the CDC. Recently, in Ashland, Oregon, 25−30% of children entering kindergarten were unvaccinated. 3 This has been attributed to elected exemption from vaccination on the basis of philosophical or religious beliefs. Vaccination rates in Europe in recent years have never fully recovered from a discredited 1998 British study linking the vaccine for measles, mumps, and rubella to autism. At that time, parents, particularly in the United Kingdom, abandoned the vaccine followed by precipitous drop in vaccination rates. For 2011, the World Health Organization reported 4937 cases of measles between January and March in France alone, as compared with 5090 cases during all of 2010. The World Health Organization reports that as of October, there have been 26000 measles cases and nine deaths in Europe since the start of 2011, rendering it the worst year for MeV activity in the Western World since 1996.
Measles is not currently treatable by drug therapy. Ribavirin, a nucleoside-based antiviral agent, is the only small molecule drug approved for paramyxoviruses (RSV) therapy. 5, 6 However, efficacy is limited. To improve case management of severe measles and achieve rapid control of outbreaks through postexposure prophylaxis, the development of an effective antimeasles drug is highly desirable. 7 We previously reported the discovery of an MeV inhibitor targeting the viral RNA-dependent RNA polymerase (RdRp) complex by means of cell-based high-throughput screening (HTS). 8, 9 Iterative optimization of a corresponding series of pyrazole carboxamides, exemplified by hit 1 (16677), led to the first-generation lead molecule 2 (AS-136a) ( Figure 1 ). 10, 11 The latter piperidine derivative exhibits superior in vitro cellular potency against MeV with nanomolar 50% effective concentrations (EC 50 ). The compound was also subjected to a number of in vitro toxicity and metabolism assays. There, the agent was found to be nonmutagenic in a non-GLP in vitro bacterial reverse mutation (Ames) assay, and it did not block hERG channels at a concentration of 10 μM or below. Compound 2 shows moderate metabolic stability in mouse and human S9 fractions after 1 h of incubation with 79 and 69% parent remaining, respectively. However, poor solubility and low rat plasma concentrations of 2 might hamper its in vivo efficacy. In an effort to improve pharmacological properties of 2, in particular water solubility, we initiated a structure−activity relationship (SAR) study to identify a suitable solubilizing group. Earlier efforts had shown that the piperidine ring is amenable to chemical manipulation without adversely affecting activity. However, any changes to the central ring or the pyrazole group of 2 are detrimental to potency. 11 Consequently, the present study focuses on appending a solubilizing group to the piperidine ring or replacing it with either a substituted phenyl or an alicyclic group. This led to the identification of compound 2o (ERDRP-00519, Figure 1 ), which has significantly improved water solubility, while retaining high antiviral potency. The agent shows a 10-fold exposure (AUC/C max ) increase in rat relative to 2 and displays near dose proportionality in the range of 10−50 mg/kg. The significant solubility increase appears to contribute to the improvement in oral bioavailability. We describe herein the synthesis and a SAR strategy that led to the discovery of 2o as well as the pharmacokinetic comparison of first-and second-generation lead candidates.
■ CHEMISTRY Synthesis of Substituted Piperidine Analogues. Our previous work showed that introduction of a piperidine moiety resulted in compounds that were about 10 times more active than the corresponding pyrrolidine analogues. 10 Accordingly, linkers were installed at the 2-, 3-, and 4-positions of the piperidine ring to explore which position could best accommodate hydrophilic substituents while maintaining potency. Reaction of different amino alcohols (4a−c) with 4-nitrobenzene sulfonyl chloride (5) followed by formation of methoxymethyl (MOM) ethers and reduction of the nitro group afforded anilines 7a−c. Coupling of acid chloride 8, derived from 3-trifluoromethyl pyrazole using the method of Lahm, 12 with anilines 7a−c provided analogues 1a−c (Scheme 1). With preliminary data showing the 2-position of the piperidine to yield more active compounds as compared to the 3-or 4-position (Table 1) , additional analogues of the previously reported 2-piperidinemethanol compound 2a 13 were prepared by a sequence similar to that depicted in Scheme 1.
Further analogues were prepared by PCC oxidation of 6a to obtain aldehyde 14, which was subjected to reductive amination with morpholine followed by the procedures illustrated in Schemes 2 to ultimately give analogue 2b. Tosylation of 6a, reduction of the nitro group, coupling with acid chloride 8, and displacement of the tosylate with an azide furnished 2c. Reduction of the azide, dimethylation of the resultant amine, or acylation resulted in compounds 2d−f. Further extension of the side chain including both saturated and unsaturated derivatives could be achieved from aldehyde 14. Horner−Wadsworth− Emmons olefination of 14 gave 12. Union of 12 with acid chloride 8 afforded analogue 2g, which was then reduced with DIBAL-H to obtain analogue 2h. Hydrogenation of 2g delivered the saturated analogue 2i, which was converted to 2j by treatment with DIBAL-H (Scheme 2).
Preparation of two-carbon side chain analogues was accomplished by utilizing 2-(2-piperidinyl) ethanol 9. Direct coupling of the latter with p-nitro-benzenesulfonyl chloride 5 gave low yields of the desired product due to further coupling of the product with the sulfonyl chloride. To circumvent this shortcoming, the NH and OH groups of 9 were protected using benzyl chloroformate 14 and t-butyldimethylsilyl chloride (TBSCl), respectively. Deprotection of the amine, coupling with 5, and reduction of the nitro group afforded aniline 11. Coupling of 11 with acid chloride 8 followed by cleavage of the silyl group furnished alcohol 2k, which, when subjected to Swern oxidation and reductive amination with morpholine, gave 2n (Scheme 3). Pure enantiomer 2o was then prepared similar to 2n starting from (S)-2-piperidine ethanol.
We hypothesized that attaching an ethylene glycol moiety would give compounds with better aqueous solubility. Because of the instability of 6a under basic conditions, the synthesis of 2p was initiated by addition of a rhodium carbenoid across the hydroxylic O−H bond 15, 16 to form an ether bond. Thus, decomposition of ethyl diazoacetate in the presence of Rh 2 OAc 4 generated a carbenoid that inserted into the OH bond to give 13. Reduction of the nitro group of 13 followed by coupling with 8 afforded analogue 2p, which on hydrolysis of the ester and BOP/NaBH 4 17 mediated reduction of the resultant carboxylic acid, provided 2q (Scheme 4).
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Synthesis of the Phenyl Series. Replacement of the piperidine ring with phenyl or substituted phenyl via the general route shown in Scheme 5 was also explored. Unsubstituted phenyl analogue 3a was found to be as active as lead compound 2, triggering an SAR study of the series ( Table 2) . Coupling of 2-methoxylthiophenol 16a with 1-fluoro-4-nitrobenzene 18 followed by oxidation of sulfur using metachloroperoxybenzoic acid (mCPBA) gave the corresponding sulfone. The nitro group was reduced followed by coupling with acid chloride 8 to furnish analogue 3b. Demethylation of 3b with BBr 3 afforded phenol analogue 3c, which upon acylation gave analogue 3d. Similarly, coupling of 2-bromothiophenol 16b with 1-fluoro-4-nitrobenzene afforded 17. To make additional analogues of the phenyl series, we envisioned utilizing bromide 17 to append substituents. However, attempts to lithiate bromide 17 using n-BuLi or t-BuLi were unfruitful, resulting in decomposition of the bromide. Stille coupling offered an alternative. When 17 was treated with tributyl(vinyl)tin in the presence of Pd(PPh 3 ) 4 , the desired coupling product 18 was obtained in 80% yield. Reduction of the nitro group followed by coupling with acid chloride 8 afforded analogue 3e (Scheme 5 and Table 2 ). Subjecting olefin 18 to osmium tetroxide-mediated oxidative cleavage of the double bond gave aldehyde 19, a compound utilized in the synthesis of additional analogues. Reduction of the aldehyde, SnCl 2 reduction of the nitro group, and protection of the alcohol as a silyl ether gave aniline 20. Coupling of 20 with acid chloride 8 followed by cleavage of the silyl group furnished analogue 3f. Aldehyde 19 was also used for the synthesis of morpholine 3g by means of reductive amination, followed by reduction of the nitro group and coupling with acid chloride 8 (Scheme 5).
Single Dose Antiviral Activity of Analogues of 2. To better understand the potency profile of compound 2 analogues, the most active analogues were subjected to a MeV yield assay at a single concentration of 1.0 μM to generate data points for comparison with 2 ( Figure 2 ).
■ RESULTS AND DISCUSSION
The SAR data are summarized in Tables 1 and 2 for the piperidine and phenyl series, respectively. From previous experience, we have learned the necessity of preserving the structure of the phenyl, amide, and fluorinated pyrazole units of the molecule to maintain antiviral potency. Modification of either the 3-trifluoromethyl-pyrazole or the central phenyl ring in most cases leads to significant loss of activity. 10, 11 All analogues listed in Tables 1 and 2 incorporate only variations on the left side of lead molecule 2. The MOM ether analogues (1a−c) demonstrate a trend whereby substitution at C-2 of piperidine is favored. The 2-piperidine 1a is 2-fold more potent than the corresponding 3-piperidine, while the 4-substituted derivatives reduce activity by almost 10-fold (1a, 1b, and 1c, Table 1 ). Piperidines bearing a hydroxyl group, elongation of the pendant chain from one carbon to two does not adversely affect potency as exemplified by compounds 2a and 2k.
Further extension to three carbons leads to a decrease in activity by 3-fold (2j, Table 1 ). Introduction of basic amines led to significant reduction or complete loss of activity (2d and 2f, EC 50 = 55.0 and >150 μM, respectively). Replacement of the amino groups with a less basic morpholine (2b and 2n) restored good potency. Esters 2g and 2i were found to be 2-fold less active by comparison with the corresponding alcohols (2h and 2j, Table 1 ). There is a clear superiority of S-chirality over R-as demonstrated by the 3-fold loss of activity for 2l compared to 2m. For the phenyl series, analogue 3a is as active as the lead compound in reducing virus-induced cytopathicity, and its activity is comparable to that of methoxy 3b and alcohol 3f (Table 3) . However, the morpholine analogue 3g loses activity completely, which stands in significant contrast to alterations in the piperidine series (2b and 2n). The previous SAR and that derived from the current three series of MeVRdRp inhibitors suggests a highly hydrophobic environment on the target protein housing the left part of the molecules, strongly disfavoring hydrogen bonding. To explore whether poor aqueous solubility contributes to the low oral bioavailability that was observed with the existing lead 2, we measured the aqueous solubility for some of the more potent derivatives via nephelometry (buffer, pH = 7.4, Table 3 ). Compound 2 and phenyl analogue 3a show equally poor solubility with values at 15 and 22 μg/mL, respectively. The alcohol analogues 2a and 2k both deliver improved solubility as expected with measured values at 61 and 62 μg/mL, respectively. Importantly, the morpholine analogue 2n also furnishes similar solubility as compared with the corresponding free alcohol derivative 2k.
Compounds with moderate solubility (∼60 μg/mL) and good potency (<3.0 μM) in the CPE assay were advanced to assessment of virus yield reduction. The primary alcohol derivative 2k (EC 50 = 2.7 μM, CPE assay; solubility 62 μg/mL) delivers an EC 50 of 100 nM in this assay (2k; Table 3 ). Optically pure analogues of compound 2k, 2l, and 2m both delivered slightly decreased potency (EC 50 = 8.3 and 3.1 μM, respectively, CPE assay). Replacement of the hydroxyl group with morpholine led to racemate 2n with an EC 50 of 4.6 μM, while the corresponding optically pure analogue 2o provided an EC 50 of 2.5 μM in the CPE assay, 60 nM in the virus yield reduction assay, and solubility around 60 μg/mL (2o; Table 3 ). Considering the significant potencies of 2k and 2o in the virus yield reduction assay (EC 50 = 100 and 60 nM, respectively), we selected these two compounds for comparison with 2 in a pharmacokinetic (PK) study in Sprague−Dawley rats.
■ PK PROFILES Figure 3 shows oral PK parameters of compounds 2k and 2o in comparison with the first generation lead 2; a summary of the numerical PK analysis is provided in Table 4 . Compound 2o shows a 10-fold exposure (with respect to both AUC and C max ) increase in the rat model relative to 2 and displays good dose proportionality in the range of 10−50 mg/kg. In contrast, the primary alcohol analogue 2k reveals a good C max and AUC at 50 mg/kg dosing, but it generates poor plasma concentrations in rat and nonproportionality possibly due to high first-pass metabolism of the primary alcohol. On the basis of its high in vitro potency, good solubility, and PK profile, the oral bioavailability of compound 2o was assessed. The compound was dosed at 2 mg/kg iv and 10 mg/kg po in rat and exhibits good oral bioavailability (F = 39%) ( Figure S1 and Table S1 in the Supporting Information). In the Caco-2 bidirectional permeability assay, both 2 and 2o showed high permeability with an efflux ratio of 1.1 and 2.6, respectively, which indicates that they are probably not a substrate for p-glycoprotein in humans ( Figure S2 in the Supporting Information). 19, 20 However, compound 2o proved to be less stable in human liver S9 fractions after 1 h of incubation. Only 24% of the parent remains as compared with 69% for compound 2. Mechanism of Action of 2o. We previously demonstrated that compound 2 blocks MeV RdRp activity by targeting the viral polymerase (L) protein. 11 To test whether this mechanism of activity likewise extends to lead molecule 2o, a plasmid-based mini-replicon assay 21 was employed to assess RdRp activity in the presence of 2o and 2, respectively. BSR-T7/5 cells were transfected with plasmid DNA encoding MeV-L, N, P, and the firefly luciferse mini-genome reporter construct, and the cells were incubated in the presence of different inhibitor concentrations or vehicle for control. Relative luciferase activities in cell lysates were assessed 36 h post-transfection, and dose− response inhibition curves were generated. For both compounds, we observed a dose-dependent inhibition of viral RdRp activity with virtually identical potency (Figure 4) , supporting a comparable mechanism of antiviral activity.
■ SUMMARY
Modification and replacement of the piperidine moiety in the first-generation lead 2, derived from our MeV-RdRp inhibitor program, has been investigated. An SAR study revealed that hydrophilicity in this molecular sector strongly influences antiviral activity. We identified compounds incorporating hydroxyl (2k) and morpholinyl (2o) moieties that furnish potencies within a 10-fold range of 2 but with much improved aqueous solubility and oral bioavailability. In the series that replaces piperidine with the phenyl group, the most promising compound was found to be 3a with antiviral activity around 90 nM in a virus yield reduction assay. Unfortunately, the solubility rates of 3a and 2 are equally low, which stands in strong contrast to analogues 2k and 2o. Accordingly, the latter were advanced to PK studies in the Sprague−Dawley rat model. Analogue 2o displays a 10-fold exposure (AUC/C max ) increase in this model relative to 2 and displays near dose proportionality in the range of 10−50 mg/kg. The Caco-2 permeability assessment demonstrated high permeability for this class of molecule. This significant solubility increase might be a major determinant for the overall improvement in oral bioavailability. Compound 2o was therefore identified as a second-generation lead for further development toward a novel measles therapeutic.
■ EXPERIMENTAL SECTION
General. Unless otherwise noted, all materials were obtained from commercial suppliers and used without purification. Dry organic solvents (DriSolv) were purchased from EMD Chemicals and packaged under nitrogen in Sure Seal bottles. Reactions were monitored using thin-layer chromatography on 250 μm plates or using Agilent 1100 series LC/MS with UV detection at 254 nm and low resonance electrospray mode (ESI). Elemental analysis was done by Atlantic Microlab. Purification of title compounds was accomplished by liquid chromatography on a Biotage SP4 purification system with normal phase silica gel. 1 H NMR spectra were recorded on a Varian spectrometer (400 MHz) at ambient temperature. Chemical shifts are reported in ppm relative to CDCl 3 or CD 3 OD, and coupling constants (J) are reported in Hertz (Hz) . Solvents for NMR were deuteriochloroform (CDCl 3 ) (residual shifts: δ 7.26 for 1 H and δ 77.7 for 13 C) and deuteriomethanol (CD 3 OD) (residual shift: δ 3.31 for 1 H). The residual shifts were taken as internal references and reported in parts per million (ppm). Purities of all compounds were ≥95% determined by high-performance liquid chromatography (HPLC) with UV detection at two wavelengths of 220 and 254 nM. Purities of key compounds were also confirmed by elemental analysis.
Typical Procedures for the Synthesis of 1-Methyl-N-(4-(piperidin-1-ylsulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides (1a−c). 4-Amino-sulfonamide 7a−c (1.0 mmol) in dichloromethane (5 mL) and pyridine (0.1 mL) was treated with 1-methyl-3-trifluoromethyl-5-pyrazolecarbonyl chloride (8) at rt. The reaction was monitored by LC/MS until no more starting material was seen, and then, the mixture was poured into saturated aqueous NaHCO 3 (10 mL) and extracted with CH 2 Cl 2 (3 × 10 mL). The CH 2 Cl 2 extracts were collected and dried over anhydrous Na 2 SO 4 . Products were purified by chromatography. The Pd/C residue was removed by filtration, followed by evaporation of the solvent. The crude product was purified by chromatography (hexane/EtOAc) to obtain amine product as white solid 70 mg (Y = 86%).
4-Amino-sulfonamide (70 mg, 0.25 mmol) in dichloromethane (5 mL) and pyridine (0.1 mL) was treated with 1-methyl-3-trifluoromethyl-5-pyrazolecarbonyl chloride (8) at rt. The reaction was monitored by LC-MS until no more starting material was seen, and then, the mixture was poured into saturated aqueous NaHCO 3 (10 mL) and extracted with CH 2 Cl 2 (3 × 10 mL). The CH 2 Cl 2 extracts were collected and dried over anhydrous Na 2 SO 4 . Products were purified by chromatography (Hex/EtOAc) to obtain product 2a as light yellow solid (81 mg, 73% General Procedure for the Synthesis of Morpholinyl Analogue (2b, 2n, and 2o). To a solution of aldehyde (1.0 mmol) in CH 2 Cl 2 (10 mL) was added morpholine (1.3 equiv, 1.3 mmol) and NaBH-(OAc) 3 (2.0 equiv, 2.0 mmol), and the mixture was kept stirring at room temperature for 3 h. NaHCO 3 (saturated aqueous) was added, and the organic layer separated and washed with brine, dried over Na 2 SO 4 , filtered, and concentrated. The product was purified by column to give morpholinyl analogue. a Study in Sprague−Dawley rat dosed at 10 and 50 mg/kg as a suspension in PEG200/0.5% methylcellulose (10/90) formulation, respectively; n = 4 animals per study. b Estimation of PK parameters by noncompartmental analysis of these data was accomplished using standard PK software (WinNonlin 5.3, Pharsight). Biology. Antiviral assays and toxicity measurements were performed as described previously. 22 ■ ASSOCIATED CONTENT * S Supporting Information Experimental details for the preparation of compounds 7a−c, 2b−j, 2o−q, 3b, 17−19, 3f, and 3g; Synthetic scheme for the synthesis of morpholinyl analogue 2o; mean plasma concentration following iv and po dosing of 2o in Sprague−Dawley rat; and summary of 2o PK properties. This material is available free of charge via the Internet at http://pubs.acs.org.
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